Entospletinib companion diagnostic - Invivoscribe
Alternative Names: Entospletinib companion diagnostic - Kronos Bio/InvivoscribeLatest Information Update: 24 Aug 2022
At a glance
- Originator Invivoscribe Technologies
- Developer Invivoscribe Technologies; Kronos Bio
- Class Diagnostic agents
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Clinical Phase Unknown Acute myeloid leukaemia